Nrf2-Keap1 in Cardiovascular Disease: Which Is the Cart and Which the Horse?

Overview

Journal Physiology (Bethesda)

Specialty Physiology

Date 2024 Apr 30

PMID 38687468

Authors

Neha Dhyani

Changhai Tian

Lie Gao

Tara L Rudebush

Irving H Zucker

Affiliations

Soon will be listed here.

Abstract

High levels of oxidant stress in the form of reactive oxidant species are prevalent in the circulation and tissues in various types of cardiovascular disease including heart failure, hypertension, peripheral arterial disease, and stroke. Here we review the role of nuclear factor erythroid 2-related factor 2 (Nrf2), an important and widespread antioxidant and anti-inflammatory transcription factor that may contribute to the pathogenesis and maintenance of cardiovascular diseases. We review studies showing that downregulation of Nrf2 exacerbates heart failure, hypertension, and autonomic function. Finally, we discuss the potential for using Nrf2 modulation as a therapeutic strategy for cardiovascular diseases and autonomic dysfunction.

Citing Articles

Targeted temperature management alleviates post-resuscitation myocardial dysfunction by inhibiting ferroptosis.

Zhang Y, Du W, Kong T, Hua T, Ma H, Hu Y Cell Death Discov. 2025; 11(1):71.

PMID: 39984437 PMC: 11845627. DOI: 10.1038/s41420-025-02356-5.

References

Schieber M, Chandel N . ROS function in redox signaling and oxidative stress. Curr Biol. 2014; 24(10):R453-62. PMC: 4055301. DOI: 10.1016/j.cub.2014.03.034. View

Priestley J, Fink K, McCord J, Lombard J . NRF2 activation with Protandim attenuates salt-induced vascular dysfunction and microvascular rarefaction. Microcirculation. 2019; 26(7):e12575. PMC: 7154587. DOI: 10.1111/micc.12575. View

Zhang D, Hannink M . Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol. 2003; 23(22):8137-51. PMC: 262403. DOI: 10.1128/MCB.23.22.8137-8151.2003. View

Kishi T, Hirooka Y, Kimura Y, Ito K, Shimokawa H, Takeshita A . Increased reactive oxygen species in rostral ventrolateral medulla contribute to neural mechanisms of hypertension in stroke-prone spontaneously hypertensive rats. Circulation. 2004; 109(19):2357-62. DOI: 10.1161/01.CIR.0000128695.49900.12. View

Banks N, Rogers E, Stanhewicz A, Whitaker K, Jenkins N . Resistance exercise lowers blood pressure and improves vascular endothelial function in individuals with elevated blood pressure or stage-1 hypertension. Am J Physiol Heart Circ Physiol. 2023; 326(1):H256-H269. PMC: 11219052. DOI: 10.1152/ajpheart.00386.2023. View

Montezano A, Burger D, Paravicini T, Chignalia A, Yusuf H, Almasri M . Nicotinamide adenine dinucleotide phosphate reduced oxidase 5 (Nox5) regulation by angiotensin II and endothelin-1 is mediated via calcium/calmodulin-dependent, rac-1-independent pathways in human endothelial cells. Circ Res. 2010; 106(8):1363-73. PMC: 3119893. DOI: 10.1161/CIRCRESAHA.109.216036. View

Park J, Do V, Seo Y, Kim H, Nam J, Yin M . NADPH Oxidase 1 Mediates Acute Blood Pressure Response to Angiotensin II by Contributing to Calcium Influx in Vascular Smooth Muscle Cells. Arterioscler Thromb Vasc Biol. 2022; 42(5):e117-e130. DOI: 10.1161/ATVBAHA.121.317239. View

Allison M, Armstrong D, Goodney P, Hamburg N, Kirksey L, Lancaster K . Health Disparities in Peripheral Artery Disease: A Scientific Statement From the American Heart Association. Circulation. 2023; 148(3):286-296. PMC: 11520198. DOI: 10.1161/CIR.0000000000001153. View

Luo Z, Aslam S, Welch W, Wilcox C . Activation of nuclear factor erythroid 2-related factor 2 coordinates dimethylarginine dimethylaminohydrolase/PPAR-γ/endothelial nitric oxide synthase pathways that enhance nitric oxide generation in human glomerular endothelial cells. Hypertension. 2015; 65(4):896-902. PMC: 4359100. DOI: 10.1161/HYPERTENSIONAHA.114.04760. View

10.

Pitra S, Stern J . A-type K channels contribute to the prorenin increase of firing activity in hypothalamic vasopressin neurosecretory neurons. Am J Physiol Heart Circ Physiol. 2017; 313(3):H548-H557. PMC: 5625174. DOI: 10.1152/ajpheart.00216.2017. View

11.

Shanmugam G, Challa A, Litovsky S, Devarajan A, Wang D, Jones D . Enhanced Keap1-Nrf2 signaling protects the myocardium from isoproterenol-induced pathological remodeling in mice. Redox Biol. 2019; 27:101212. PMC: 6859568. DOI: 10.1016/j.redox.2019.101212. View

12.

Lewis G, Docherty K, Voors A, Cohen-Solal A, Metra M, Whellan D . Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF. Circ Heart Fail. 2022; 15(5):e008970. DOI: 10.1161/CIRCHEARTFAILURE.121.008970. View

13.

Dellacqua L, Gomes P, Batista J, Michelini L, Antunes V . Exercise-induced neuroplasticity in autonomic nuclei restores the cardiac vagal tone and baroreflex dysfunction in aged hypertensive rats. J Appl Physiol (1985). 2023; 136(1):189-198. DOI: 10.1152/japplphysiol.00433.2023. View

14.

Ignarro L, Napoli C, Loscalzo J . Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ Res. 2002; 90(1):21-8. DOI: 10.1161/hh0102.102330. View

15.

Sarrion I, Milian L, Juan G, Ramon M, Furest I, Carda C . Role of circulating miRNAs as biomarkers in idiopathic pulmonary arterial hypertension: possible relevance of miR-23a. Oxid Med Cell Longev. 2015; 2015:792846. PMC: 4357130. DOI: 10.1155/2015/792846. View

16.

Schnackenberg C, Wilcox C . Two-week administration of tempol attenuates both hypertension and renal excretion of 8-Iso prostaglandin f2alpha. Hypertension. 1999; 33(1 Pt 2):424-8. DOI: 10.1161/01.hyp.33.1.424. View

17.

Liu L, Zhang X, Zhang R, Wang L, Zhi S, Feng X . Sohlh2 promotes pulmonary fibrosis via repression of p62/Keap1/Nrf2 mediated anti-oxidative signaling pathway. Cell Death Dis. 2023; 14(10):698. PMC: 10598036. DOI: 10.1038/s41419-023-06179-z. View

18.

Wang C, Luo Z, Carter G, Wellstein A, Jose P, Tomlinson J . NRF2 prevents hypertension, increased ADMA, microvascular oxidative stress, and dysfunction in mice with two weeks of ANG II infusion. Am J Physiol Regul Integr Comp Physiol. 2017; 314(3):R399-R406. PMC: 5899246. DOI: 10.1152/ajpregu.00122.2017. View

19.

Rogers R, Ciullo A, Marban E, Ibrahim A . Extracellular Vesicles as Therapeutic Agents for Cardiac Fibrosis. Front Physiol. 2020; 11:479. PMC: 7255103. DOI: 10.3389/fphys.2020.00479. View

20.

Minatoguchi S . Heart failure and its treatment from the perspective of sympathetic nerve activity. J Cardiol. 2021; 79(6):691-697. DOI: 10.1016/j.jjcc.2021.11.016. View